Related Experiment Video
Updated: Jul 30, 2025
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
Published on: August 23, 2019
Inhibitory Effect of Phosphorothioate Oligonucleotide Complementary to G6PD mRNA on Murine Melanoma
Kseniya A Yurchenko1, Kateryna V Laikova2, Ilya O Golovkin2
1Department of Molecular Genetics and Biotechnologies, Institute of Biochemical Technologies, Ecology and Pharmacy, V.I. Vernadsky Crimean Federal University, 295007 Simferopol, Russia.
Abstract:
In terms of the incidence among all tumors, skin cancer is on top, with the most deadly among them being melanoma. The search for new therapeutic agents to combat melanoma is very relevant. In our opinion, antisense oligonucleotides (ASO) aimed at suppressing the genes responsible for their viability in cancer cells give hope for treatment, which makes it possible to eliminate cancer cells near the tumor site both before and after surgery. In this article, we describe how Skeen-11 phosphorothioate oligonucleotide significantly decreased the proliferative activity of murine melanoma cells. Injections of Skeen-11 also inhibited tumor growth in mice with inoculated melanoma. A toxicity study showed no side effects with dose adjustments. The results show that the use of ASO Skeen-11 in vivo reduced the tumor size within 7 days, reduced the number of mitoses in the tumor cells, and increased the amount of necrosis compared with the control group.
Insights
Antisense oligonucleotides (ASO) like Skeen-11 show promise for melanoma treatment by reducing cancer cell proliferation and tumor growth in mice. This novel approach offers a potential new therapy with minimal observed side effects.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Melanoma is the deadliest form of skin cancer, necessitating novel therapeutic strategies.
- Antisense oligonucleotides (ASO) offer a targeted approach to suppress cancer-promoting genes.
Purpose of the Study:
- To evaluate the efficacy of Skeen-11, a phosphorothioate oligonucleotide, in treating murine melanoma.
- To assess the in vivo anti-tumor activity and toxicity of Skeen-11.
Main Methods:
- Treatment of murine melanoma cells and tumor-bearing mice with Skeen-11.
- Assessment of cell proliferative activity, tumor growth inhibition, and histopathological changes (mitosis, necrosis).
- Conducting a toxicity study with dose adjustments.
Main Results:
- Skeen-11 significantly decreased the proliferative activity of melanoma cells in vitro.
- In vivo administration of Skeen-11 inhibited melanoma tumor growth in mice.
- Reduced tumor size, decreased mitosis, and increased necrosis were observed within 7 days.
- Toxicity studies indicated no adverse effects with appropriate dose adjustments.
Conclusions:
- Skeen-11 demonstrates significant anti-melanoma activity in vitro and in vivo.
- ASO Skeen-11 represents a promising therapeutic candidate for melanoma treatment.
- The targeted gene suppression by ASO offers a potential strategy for cancer therapy with a favorable safety profile.
More Related Videos
10:49A Murine Cell Line Based Model of Chronic CDK9 Inhibition to Study Widespread Non-Genetic Transcriptional Elongation Defects TEdeff in Cancers
Published on: September 26, 2019
06:09Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
Published on: June 7, 2019
